Organization
Hellenic Society of Hematology
4 clinical trials
Clinical trial
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible (EAE 120)Status: Recruiting, Estimated PCD: 2026-03-15
Clinical trial
Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal ImpairmentStatus: Completed, Estimated PCD: 2021-03-22
Clinical trial
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administrated in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
A Phase 1/2 Study of Belantamab Mafodotin in Combination With Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2028-09-08